Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP3K12 | Q12852 | 5/20 | 0.35 |
| ▸ | CNR2 | P34972 | 4/20 | 0.35 |
| ▸ | ACACB | O00763 | 1/20 | 0.32 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.32 |
| ▸ | TNNI3K | Q59H18 | 1/20 | 0.32 |
| ▸ | EIF2AK4 | Q9P2K8 | 1/20 | 0.32 |
| ▸ | SORD | Q00796 | 1/20 | 0.31 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | DPP4 | P27487 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17581373 | 0.89 | CNR2 (0.41) | MAP3K12CNR2SORDDPP4 | |
| SCHEMBL38656894 | 0.82 | CNR2 (0.40) | MAP3K12CNR2DPP4 | |
| SCHEMBL38656893 | 0.82 | CNR2 (0.40) | MAP3K12CNR2DPP4 | |
| SCHEMBL24851154 | 0.77 | CASP1 (0.39) | CNR2EIF2AK4CYP1A2SMN1; SMN2DPP4 | |
| SCHEMBL24851153 | 0.77 | CASP1 (0.43) | MAP3K12CNR2CYP1A2CYP2D6 | |
| SCHEMBL31171509 | 0.76 | MAPK1 (0.34) | CNR2SORDALDH1A1CYP2D6HSD17B10 | |
| SCHEMBL31171487 | 0.76 | MAPK1 (0.34) | CNR2SORDALDH1A1CYP2D6HSD17B10 | |
| SCHEMBL9336873 | 0.74 | HRH1 (0.50) | SORDALDH1A1CYP1A2CYP2D6HSD17B10 | |
| SCHEMBL778332 | 0.72 | SMN1; SMN2 (0.52) | SORDALDH1A1CYP1A2CYP2D6HSD17B10 | |
| SCHEMBL2242665 | 0.72 | SMN1; SMN2 (0.52) | SORDALDH1A1CYP1A2CYP2D6HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11584757-B2 | MK2 inhibitors and uses thereof | CELGENE CAR LLC (BM) | 2023-02-21 | — | — | US | disclosed |
| US-11584757-B2 | MK2 inhibitors and uses thereof | CELGENE CAR LLC (BM) | 2023-02-21 | — | — | US | disclosed |
| EP-3912981-A1 | MK2 INHIBITORS AND USES THEREOF | CELGENE CAR LLC (BM) | 2021-11-24 | — | — | EP | disclosed |
| EP-3912981-A1 | MK2 INHIBITORS AND USES THEREOF | CELGENE CAR LLC (BM) | 2021-11-24 | — | — | EP | disclosed |
| EP-3193611-B1 | MK2 INHIBITORS AND USES THEREOF | CELGENE CAR LLC (BM) | 2021-03-24 | — | — | EP | disclosed |
| EP-3193611-B1 | MK2 INHIBITORS AND USES THEREOF | CELGENE CAR LLC (BM) | 2021-03-24 | — | — | EP | disclosed |
| US-20210053984-A1 | MK2 INHIBITORS AND USES THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2021-02-25 | — | — | US | disclosed |
| US-20210053984-A1 | MK2 INHIBITORS AND USES THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2021-02-25 | — | — | US | disclosed |
| CN-106998692-B | MK2 inhibitors and uses thereof | 西建卡尔有限责任公司 | 2020-09-08 | — | — | CN | disclosed |
| US-10577380-B2 | MK2 inhibitors and uses thereof | CELGENE CAR LLC (BM) | 2020-03-03 | — | — | US | disclosed |
| US-20170114073-A1 | MK2 INHIBITORS AND USES THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2017-04-27 | — | — | US | disclosed |
| US-20170114073-A1 | MK2 INHIBITORS AND USES THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2017-04-27 | — | — | US | disclosed |
| US-20170114073-A1 | MK2 INHIBITORS AND USES THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2017-04-27 | — | — | US | disclosed |
| US-9458175-B2 | MK2 inhibitors and uses thereof | CELGENE AVILOMICS RESEARCH, INC. (US) | 2016-10-04 | — | — | US | disclosed |
| US-9458175-B2 | MK2 inhibitors and uses thereof | CELGENE AVILOMICS RESEARCH, INC. (US) | 2016-10-04 | — | — | US | disclosed |
| US-9458175-B2 | MK2 inhibitors and uses thereof | CELGENE AVILOMICS RESEARCH, INC. (US) | 2016-10-04 | — | — | US | disclosed |
| WO-2016044463-A2 | MK2 INHIBITORS AND USES THEREOF | CELGENE AVILOMICS RESEARCH, INC. (US) | 2016-03-24 | — | — | WO | disclosed |
| WO-2016044463-A2 | MK2 INHIBITORS AND USES THEREOF | CELGENE AVILOMICS RESEARCH, INC. (US) | 2016-03-24 | — | — | WO | disclosed |
| US-20160075720-A1 | MK2 INHIBITORS AND USES THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2016-03-17 | — | — | US | disclosed |
| US-20160075720-A1 | MK2 INHIBITORS AND USES THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2016-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10577380-B2 | MK2 inhibitors and uses thereof | MKNK2, DUSP2, MKNK1 | MAP3K12 24/4885CNR2 1189/4885ACACB 437/4885 |
| US-20170114073-A1 | MK2 INHIBITORS AND USES THEREOF | MKNK2, DUSP2, MKNK1 | MAP3K12 24/4885CNR2 1189/4885ACACB 437/4885 |
| US-20160075720-A1 | MK2 INHIBITORS AND USES THEREOF | MKNK2, DUSP2, MKNK1 | MAP3K12 24/4885CNR2 1189/4885ACACB 437/4885 |
| US-11584757-B2 | MK2 inhibitors and uses thereof | MKNK2, DUSP2, MKNK1 | MAP3K12 24/4885CNR2 1189/4885ACACB 437/4885 |
| US-20210053984-A1 | MK2 INHIBITORS AND USES THEREOF | MKNK2, DUSP2, MKNK1 | MAP3K12 24/4885CNR2 1189/4885ACACB 437/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.